Comments
Drug firm Lupin today said it has received approval from the US health regulator to sell its potassium chloride oral solution used for the treatment of low potassium levels in the American market.
The company has received approval to market its potassium chloride oral solution USP, in the strengths of 20 mEq/15 ml (10 per cent) and 40 mEq/15 ml (20 per cent) from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
The company’s product is a generic version of Genus Lifesciences Inc’s potassium chloride oral solution in the same strengths, it added. According to IQVIA MAT June 2018 data the oral solution in the two strengths had annual sales of around $184.95 million in the US, Lupin said.
“The product is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient,” it added.
Shares of Lupin Ltd were trading at Rs 933.35 on BSE, up 4.44 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.